ANDA 202507, held by Xiromed. Ethinyl Estradiol; Levonorgestrel.
As of Nov 16, 2026, ANDA 202507 (Elifemme), held by Xiromed, was first approved by FDA on Dec 4, 2015, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 4, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Elifemme0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG · tablet;oral-28 | Ethinyl Estradiol; Levonorgestrel | Discontinued |
| Apr 29, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 9, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 24, 2017 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 4, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters